Seminars in Oncology
Volume 33 , Pages S8-S14 , October 2006

Bevacizumab in Combination With Chemotherapy: First-Line Treatment of Patients With Metastatic Colorectal Cancer

  • Howard S. Hochster

      Affiliations

    • Dr Hochster is a consultant to Sanofi-Aventis, Genentech, and OSI Pharmaceuticals.
    • Corresponding Author InformationAddress reprint requests to Howard S. Hochster, MD, Department of Medicine, New York University Cancer Institute, 160 East 34th St, New York, NY 10016, USA.

References 

  1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1027
  2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  3. Hedrick EE, Hurwitz H, Sarkar S, et al. Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol. 2004;22:249s;(abstr 3517)
  4. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;16:3706–3712
  5. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65
  6. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–3705
  7. Fyfe GA, Hurwitz I, Fehrenbacher T, et al. Bevacizumab plus irinotecan/5-FU/leucovorin for the treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol. 2004;22:274;(abstr 3617)
  8. Werther K, Christensen IJ, Brunner N, et al. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma (The Danish RANX05 Colorectal Cancer Study Group). Eur J Surg Oncol. 2000;26:657–662
  9. Nakayama Y, Sako T, Shibao K, et al. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res. 2002;22:2437–2442
  10. Holden SN, Ryan E, Kearns A, et al. Benefit from bevacizumab is independent of pretreatment plasma vascular endothelial growth factor-A in patients with metastatic colorectal cancer. J Clin Oncol. 2005;23(suppl):259s;(abstr 3555)
  11. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217–227
  12. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981–989
  13. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Final analysis of the TREE study. J Clin Oncol. 2006;24(suppl):(abstr 3510)
  14. Bendell J, Fernando N, Morse M, et al. A phase II study of oxaliplatin, capecitabine, and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol. 2006;24(suppl):156s;(abstr 3541)
  15. Kopetz S, Eng C, Adinin RB, et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). J Clin Oncol. 2006;24(suppl):165s;(abstr 3579)
  16. Grothey A, Hedrick EE, Mass RD, et al. Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): A comparative analysis of N9741 and AVF2107. J Clin Oncol. 2006;24(suppl):165s;(abstr 3516)
  17. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30
  18. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222-584 or placebo (CONFIRM-1). J Clin Oncol. 2005;23(suppl):2s;(abstr 3)
  19. Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 or placebo (CONFIRM 2). J Clin Oncol. 2006;24(suppl):148s;(abstr 3508)
  20. Major P, Trarbach T, Lenz H-J. Meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients with metastatic colorectal cancer receiving FOLFOX4 and PTK/ZK to determine clinical benefit using progression-free survival in high LDH patients. J Clin Oncol. 2006;24(suppl):153s;(abstr 3529)

PII: S0093-7754(06)00316-2

doi: 10.1053/j.seminoncol.2006.08.005

Seminars in Oncology
Volume 33 , Pages S8-S14 , October 2006

Article Tools

* Image Usage & Resolution